ZEJULA (niraparib) recall in Canada: New safety information
In plain language
This recall involves ZEJULA (niraparib) 100 mg capsules and tablets sold in Canada. It's being recalled because new safety information suggests overall survival may be lower for some patients. Patients currently taking ZEJULA should contact their healthcare professional for more information.
What to do
- Stop using the product immediately.
- Contact your healthcare professional for more information.
- Discuss this information with your doctor to make an informed decision about your treatment plan.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
ZEJULA (niraparib)
Why this matters
Reduced overall survival
Do I have this product?
This recall only applies to specific products. Follow the steps below to check.
- 1
Check the product name
Make sure your product name matches one of the affected products listed above.
If your product matches one or more of the details above, it may be affected by this recall.
If your product does not match these details, it is not affected by this recall.
When in doubt, always check the official notice.
Frequently Asked Questions
Why was this product recalled?
Reduced overall survival
What should consumers do?
Stop using the product immediately. Contact your healthcare professional for more information. Discuss this information with your doctor to make an informed decision about your treatment plan.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
Yes, there may be a health risk. Reduced overall survival
When was this product recalled?
This product was recalled on February 16, 2023.
Is the ZEJULA brand affected by this recall?
Yes, ZEJULA products are affected by this recall. This recall involves ZEJULA (niraparib) 100 mg capsules and tablets sold in Canada. It's being recalled because new safety information suggests overall survival may be lower for some patients. Patients currently taking ZEJULA should contact their healthcare professional for more information.